McKesson Lifts Fiscal 2027 Earnings Outlook Following Strong Q2 Growth

McKesson Corporation reported strong financial results for its second quarter of fiscal 2027, driven by expanding pharmaceutical distribution and demand for GLP-1 medications. Quarterly revenue increased 8% year over year to $111.0 billion, while Simply Wall St reported sales at US$110.957b and net income of US$1.218b. Adjusted earnings per diluted share climbed 18% to $11.68, up from $9.86 a year earlier, supported by operating growth and a lower share count.

Following the quarterly performance, McKesson raised its fiscal 2027 adjusted earnings outlook to a range of $45.60 to $46.40 per diluted share, up from the prior target of $44.20 to $45.00. The revised range represents an expected increase of 17% to 19% compared with the prior fiscal year. Chief Executive Officer Brian Tyler pointed to ongoing operational strength, while Chief Financial Officer Kenny Cheung stated that the higher guidance reflects confidence in consistent execution across the business.

Core divisions delivered broad gains during the quarter. North American Pharmaceutical revenue advanced 6% to $91.4 billion, and its adjusted operating profit grew 22% to $1.0 billion. Oncology & Multispecialty revenue surged 24% to $15.0 billion, and Prescription Technology Solutions revenue rose 10% to $1.5 billion. In contrast, Medical-Surgical Solutions adjusted segment operating profit fell 10% to $225 million due to product mix shifts in the ambulatory care channel, despite a 5% revenue increase to $3.1 billion.

The distributor also advanced its strategic expansion by closing its purchase of Precision Medicine Group on November 2, 2026, aimed at strengthening its biopharma and oncology services. Additionally, the company entered into an agreement to acquire an approximate 49% stake in Option Care Health for roughly $1.4 billion, which remains subject to regulatory and shareholder conditions. During the first six months of the fiscal year, McKesson returned $3.6 billion to shareholders, including $3.4 billion in share repurchases and $198 million in dividends.

Wall Street sentiment has adjusted following the quarterly update. Morgan Stanley raised its price target for McKesson to $1,260 from $1,207 on November 5 and kept an Overweight rating. While the stock closed recently at $1,082.59, an analyst consensus narrative on Simply Wall St estimated fair value at $1,026.07, noting potential headwinds from drug pricing regulation and a recent cyber incident. Conversely, the Simply Wall St discounted cash flow model projected an estimated future cash flow value of $1,980.95.